Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Bayer and KYTHERA in Potential $330M Licensing Agreement

By Pharmaceutical Processing | August 31, 2010

KYTHERA Biopharmaceuticals, Inc. and Intendis, Bayer HealthCare’s  dermatology business, have entered into a licensing agreement granting Intendis rights to KYTHERA’s lead product candidate, ATX-101, outside of the US and Canada. ATX-101, a  first-in-class investigational drug, is currently in clinical development for the reduction of localized fat under the chin (submental fat).

Under the terms of the agreement, KYTHERA will receive an upfront  payment of $43 million and may be eligible to receive up to $330  million for certain development, manufacturing and commercialization  milestones. Additionally, KYTHERA will also receive tiered double digit royalties based on net sales in Intendis’ territories. The  agreement encompasses all potential indications with KYTHERA to retain  development and commercialization rights to ATX-101 in the US and  Canada.

Intendis, Bayer HealthCare’s dermatology business, will be collaborating with KYTHERA to execute the currently planned ex-US Phase 3 clinical trials that are expected to start in Europe in late  2010.

“In evaluating multiple partners, we were particularly impressed with  Intendis’ vision and commitment to building a new franchise in  aesthetic medicine to complement their existing business in dermatology. Moreover, their footprint either directly or through the Bayer family of companies provides a strong commercial presence  worldwide,” said Keith Leonard, KYTHERA’s President and CEO. “Based on  the results we have seen from the two Phase 2 studies, we believe ATX-101 has the potential to become an important tool for physicians  and their patients. We are convinced that the long-standing  partnership that Intendis has established with dermatologists  worldwide is an excellent basis for the successful introduction of  ATX-101 outside the United States.”

“As a business fully dedicated to dermatology, we are well aware of  the changing needs that dermatologists are facing in their daily  practice,” said Marc Lafeuille, President and CEO of Intendis. “As a first-in-class candidate being studied for minimally-invasive fat  reduction, we see ATX-101 as a strong growth opportunity and an  excellent entry point into the aesthetic dermatology business. The agreement with KYTHERA will allow us to fully leverage both our long-standing expertise in pharmaceutical development, as well as our  strong foothold with the dermatologist.”     

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE